The Lancet

Journal

Publication Venue For

  • Balloon catheters versus vaginal prostaglandins for labour induction (CPI Collaborative): an individual participant data meta-analysis of randomised controlled trials.  400:1681-1692. 2022
  • Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.  400:1405-1416. 2022
  • The North American opioid crisis: educational failures and incautious stoppage.  400:1402. 2022
  • Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission.  400:921-972. 2022
  • Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019.  398:1593-1618. 2021
  • Fatal police violence by race and state in the USA, 1980–2019: a network meta-regression.  398:1239-1255. 2021
  • Cardiovascular safety of febuxostat.  398:955. 2021
  • Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019.  398:870-905. 2021
  • Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.  397:2476-2486. 2021
  • An action plan for pan-European defence against new SARS-CoV-2 variants.  397:469-470. 2021
  • Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.  396:1994-2005. 2020
  • Five insights from the Global Burden of Disease Study 2019.  396:1135-1159. 2020
  • Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019.  396:1160-1203. 2020
  • Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.  396:1204-1222. 2020
  • Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.  396:1223-1249. 2020
  • Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.  396:1250-1284. 2020
  • Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.  396:839-852. 2020
  • Transparency and diversity in cystic fibrosis research – Authors' reply.  396:602. 2020
  • Department of Error: Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017 (The Lancet (2020) 395(10239) (1779–1801), (S0140673620301148), (10.1016/S0140-6736(20)30114-8)).  395:1762. 2020
  • Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: Analysis for the Global Burden of Disease Study 2017.  395:1779-1801. 2020
  • Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.  395:709-733. 2020
  • ECHO: context and limitations.  395:e23. 2020
  • Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial.  395:285-293. 2020
  • Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.  394:1940-1948. 2019
  • What is the first choice for blood pressure treatment?.  394:1782-1784. 2019
  • Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.  394:1352-1363. 2019
  • Erratum: Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1923–1994), (S0140673618322256), (10.1016/S0140-6736(18)32225-6)).  393:e44. 2019
  • Towards eradication of chronic obstructive pulmonary disease: a Lancet Commission.  393:1786-1788. 2019
  • Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial.  393:1021-1032. 2019
  • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.  393:143-155. 2019
  • Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.  393:40-50. 2019
  • Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.  392:2269-2279. 2018
  • Erratum: Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1736–1788)(S0140673618322037)(10.1016/S0140-6736(18)32203-7)).  392:2170. 2018
  • Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: A systematic analysis for the Global Burden of Disease Study 2017.  392:1684-1735. 2018
  • Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017.  392:1736-1788. 2018
  • Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017.  392:1923-1994. 2018
  • Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017.  392:1859-1922. 2018
  • Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017.  392:1789-1858. 2018
  • Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017.  392:2091-2138. 2018
  • Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017.  392:1995-2051. 2018
  • Revisiting ASCOT 16 years later.  392:1092-1094. 2018
  • Alcohol use and burden for 195 countries and territories, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016.  392:1015-1035. 2018
  • Updated Zika virus recommendations are needed.  392:818-819. 2018
  • Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: A systematic analysis from the Global Burden of Disease Study 2016.  391:2236-2271. 2018
  • Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.  391:205-218. 2018
  • Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.  391:219-229. 2018
  • The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE).  390:2569-2582. 2017
  • Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial.  390:2143-2159. 2017
  • Erratum: Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016 (The Lancet (2017) 390(10100) (1423–1459) (S014067361732336X) (10.1016/S0140-6736(17)32336-X)).  390:e38. 2017
  • Erratum:Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016 (The Lancet (2017) 390(10100) (1423–1459) (S014067361732336X)(10.1016/S0140-6736(17)32336-X)).  390:e23. 2017
  • Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016.  390:1151-1210. 2017
  • Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016.  390:1345-1422. 2017
  • Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016.  390:1260-1344. 2017
  • Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016.  390:1211-1259. 2017
  • Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: A systematic analysis for the Global Burden of Disease Study 2016.  390:1084-1150. 2017
  • Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: An analysis from the Global Burden of Disease Study 2016.  390:1423-1459. 2017
  • Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.  390:849-860. 2017
  • Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: A novel analysis from the global burden of disease study 2015.  390:231-266. 2017
  • Novel influenza A viruses and pandemic threats.  389:2172-2174. 2017
  • Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: A systematic analysis from the global burden of disease study 2015.  389:1885-1906. 2017
  • Syphilis.  389:1550-1557. 2017
  • 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.  389:1399-1409. 2017
  • Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial.  389:603-611. 2017
  • Erratum: Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (The Lancet (2016) 388(10053) (1775–1812)(S0140673616314702)(10.1016/S0140-6736(16)31470-2)).  389:e1. 2017
  • Erratum: Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 (The Lancet (2016) 388(10053) (1725–1774)(S0140673616315756)(10.1016/S0140-6736(16)31575-6)).  389:e1. 2017
  • Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.  388:2763-2774. 2016
  • Gout.  388:2039-2052. 2016
  • Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.  388:1659-1724. 2016
  • Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.  388:1603-1658. 2016
  • Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.  388:1545-1602. 2016
  • Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.  388:1775-1812. 2016
  • Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015.  388:1459-1544. 2016
  • Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015.  388:1725-1774. 2016
  • Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015.  388:1813-1850. 2016
  • Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.  388:661-672. 2016
  • Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma.  387:1881-1882. 2016
  • Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): A multicountry open-label randomised controlled trial.  387:1198-1209. 2016
  • Zika virus and microcephaly: Why is this situation a PHEIC?.  387:719-721. 2016
  • Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: Complete follow-up results from the CHAMPION randomised trial.  387:453-461. 2016
  • Oseltamivir for influenza - Authors' reply.  387:125. 2016
  • Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013.  386:2287-2323. 2015
  • Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: Quantifying the epidemiological transition.  386:2145-2191. 2015
  • Authors reply.  386:1135-1136. 2015
  • Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013.  386:743-800. 2015
  • Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis.  386:258-265. 2015
  • Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials.  385:2606-2615. 2015
  • Oseltamivir treatment for influenza in adults: A meta-analysis of randomised controlled trials.  385:1729-1737. 2015
  • Financial contribution to global surgery: an analysis of 160 international charitable organisations..  385 Suppl 2:S52. 2015
  • Funding flows to global surgery: an analysis of contributions from the USA..  385 Suppl 2:S51. 2015
  • Mapping the playing field-a novel web-based strategy to identify non-governmental actors in global surgery..  385 Suppl 2:S55. 2015
  • A population-based, multifaceted strategy to implement antenatal corticosteroid treatment versus standard care for the reduction of neonatal mortality due to preterm birth in low-income and middle-income countries: The ACT cluster-randomised trial.  385:629-639. 2015
  • Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013.  385:117-171. 2015
  • Global, regional, and national levels and causes of maternal mortality during 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013.  384:980-1004. 2014
  • Wiping versus suction to clear neonatal airways at birth - Authors' reply..  383:695-696. 2014
  • Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): The final results of a randomised trial.  383:333-341. 2014
  • Authors' reply.  383:695-696. 2014
  • EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: A randomised, double-blind, placebo-controlled phase 2 clinical trial.  383:1637-1647. 2014
  • Erratum: Individualised pelvic fl oor muscle training in women with pelvic organ prolapse (POPPY): A multicentre randomised controlled trial (The Lancet (2014) 383 (760-62)).  384:28. 2014
  • Erratum: Pelvic floor muscle training for pelvic organ prolapse (Lancet (2014) 383 (760-762)).  384:28. 2014
  • Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013.  384:1005-1070. 2014
  • Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013.  384:957-979. 2014
  • Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013.  384:766-781. 2014
  • New oral anticoagulants in patients with atrial fibrillation (1).  384:23-24. 2014
  • Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.  383:2222-2231. 2014
  • Pelvic floor muscle training for pelvic organ prolapse.  383:760-762. 2014
  • Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial..  382:507-515. 2013
  • Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial.  381:125-132. 2013
  • Genetic variants associated with warfarin dose in African-American individuals: A genome-wide association study.  382:790-796. 2013
  • Oronasopharyngeal suction versus wiping of the mouth and nose at birth: A randomised equivalency trial.  382:326-330. 2013
  • Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010.  380:2197-2223. 2012
  • Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010.  380:2095-2128. 2012
  • A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010.  380:2224-2260. 2012
  • Effect of the Affordable Medicines Facility - Malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: A before-and-after analysis of outlet survey data.  380:1916-1926. 2012
  • Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study.  380:2007-2017. 2012
  • Erratum: Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial (The Lancet (2011) 377 (658-666)).  379:412. 2012
  • Leukaemia cutis.  380:1179. 2012
  • Physical activity for people with disabilities.  380:193-195. 2012
  • The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial.  380:1387-1395. 2012
  • Treatment of Helicobacter pylori in Latin America - Authors' reply.  379:408-409. 2012
  • Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010.  380:2163-2196. 2012
  • Addressing Mississippi's HIV/AIDS crisis..  378:1217. 2011
  • 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: A randomised trial.  378:507-514. 2011
  • Eltrombopag for chronic immune thrombocytopenia - Authors' reply.  377:1919-1920. 2011
  • Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study.  377:393-402. 2011
  • Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study (Lancet (2011) 377, (393-402)).  377:640. 2011
  • Prevention of cardiovascular disease in adult recipients of kidney transplants.  378:1419-1427. 2011
  • Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial.  378:238-246. 2011
  • Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial.  377:658-666. 2011
  • Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.  375:2073-2081. 2010
  • Enzyme replacement therapy for Fabry's disease.  375:1523. 2010
  • Serological surveys for 2009 pandemic influenza A H1N1.  375:1062-1063. 2010
  • Triglyceride-mediated pathways and coronary disease: Collaborative analysis of 101 studies.  375:1634-1639. 2010
  • Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.  374:1597-1605. 2009
  • Second primary cancers in survivors of childhood cancer.  374:1484-1485. 2009
  • Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.  373:1253-1263. 2009
  • Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial.  371:228-236. 2008
  • Dual inhibition of the renin system by aliskiren and valsartan.  370:1126-1127. 2007
  • Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.  370:221-229. 2007
  • VALIDD should not invalidate angiotensin-receptor blockers.  369:2053-2054. 2007
  • Metastasis: recent discoveries and novel treatment strategies.  369:1742-1757. 2007
  • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial.  368:1096-1105. 2006
  • Emergency management of seizures in children.  367:1555-1556. 2006
  • Authors' reply [8].  367:729. 2006
  • Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.  367:475-481. 2006
  • Lymphoproliferative disorders after paediatric heart transplantation: A multi-institutional study.  367:233-239. 2006
  • Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trial.  366:1435-1442. 2005
  • Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: A preclinical study.  366:1005-1012. 2005
  • Cytomegalovirus and HIV: Inextricably entwined pathogens.  363:2101-2102. 2004
  • Transmission of HIV-1 and HLA-B allele-sharing within serodiscordant heterosexual Zambian couples.  363:2137-2139. 2004
  • Insulinomas and expression of an insulin splice variant.  363:363-367. 2004
  • Physical activity and obesity.  363:182. 2004
  • Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1 [4].  362:667. 2003
  • More on ISAT [4] (multiple letters).  361:783-784. 2003
  • Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy.  361:491-492. 2003
  • Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer.  360:1557-1563. 2002
  • Barriers to HIV testing - Where next?.  360:1186-1187. 2002
  • Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial.  359:2053-2058. 2002
  • Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol.  359:1004-1010. 2002
  • Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol.  359:995-1003. 2002
  • Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: An observational study.  359:926-930. 2002
  • Viral encephalitis: Familiar infections and emerging pathogens.  359:507-513. 2002
  • Missing HIV kits in Pakistan [2] (multiple letters).  358:923-924. 2001
  • Smoking cessation in patients with chronic obstructive pulmonary disease: A double-blind, placebo-controlled, randomised trial.  357:1571-1575. 2001
  • Herpes simplex virus infections.  357:1513-1518. 2001
  • Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios.  357:1438-1440. 2001
  • Myoblast transplantation for heart failure.  357:279-280. 2001
  • Myoblast transplantation for heart failure.  357:279-280. 2001
  • Hormone replacement therapy and serum uric acid (multiple letters) [3].  354:1643-1644. 1999
  • Hormone replacement therapy and serum uric acid..  354:1643. 1999
  • Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: A randomised controlled trial.  354:1061-1065. 1999
  • Pneumocystis carinii genotypes and severity of pneumonia.  353:2039-2040. 1999
  • Constraint-induced movement therapy for focal hand dystonia in musicians.  353:42. 1999
  • Choriodecidual inflammation: A potentially preventable cause of perinatal HIV-1 transmission?.  352:1927-1930. 1998
  • β-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-α-lipoproteinaemia.  351:1919-1923. 1998
  • Sex ratio of offspring of diabetics (multiple letters) [8].  351:1514-1516. 1998
  • Tocolytic magnesium sulphate and paediatric mortality [2].  351:290-291. 1998
  • Analysis of the α-synuclein G209A mutation in familial Parkinson's disease [7].  351:37-38. 1998
  • Is elimination of endemic syphilis transmission a realistic goal for the USA?.  351:19-21. 1998
  • Is elimination of endemic syphilis transmission a realistic goal for the USA?.  351 Suppl 3:19-21. 1998
  • Sexually transmitted diseases..  352:651. 1998
  • Tocolytic magnesium sulphate and paediatric mortality..  351. 1998
  • Field trial of a rapid card test for Wuchereria bancrofti.  350:1681. 1997
  • Vector-parasite transmission complexes for onchocerciasis in West Africa.  349:163-166. 1997
  • Family history of patients with breast cancer after treatment of Hodgkin's disease in childhood [18].  350:888-889. 1997
  • Phyto-oestrogens and breast cancer.  350:971-972. 1997
  • HIV-associated respiratory diseases.  348:307-312. 1996
  • Abortion and fertility regulation.  347:1663-1668. 1996
  • Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma.  346:799-802. 1995
  • Association of human herpes virus with pulmonary Kaposi's sarcoma.  346:712. 1995
  • When to use fluconazole.  345:1305. 1995
  • Diagnosis of Chlamydia trachomatis genitourinary infection in women by ligase chain reaction assay of urine.  345:213-216. 1995
  • When to use fluconazole.  345:6-7. 1995
  • CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group..  343:619-629. 1994
  • Potassium channels in colonic crypts.  343:23-25. 1994
  • Cross-reactivity between Stomatococcus mucilaginosus and latex agglutination for cryptococcal antigen.  342:1119-1120. 1993
  • Apolipoprotein E genotype and Alzheimer's disease.  342:737-738. 1993
  • Apolipoprotein E genotype and Alzheimer's disease..  342:738. 1993
  • Viral dynamics in primary HIV-1 infection.  341:1099. 1993
  • Viral dynamics in primary HIV-1 infection [21].  341:1099. 1993
  • Seasonal variation in presentation of Pneumocystis carinii pneumonia.  339:747-748. 1992
  • Pentamidine prophylaxis with a metered-dose inhaler.  337:1489. 1991
  • DNA amplification on induced sputum samples for diagnosis of Pneumocystis carinii pneumonia.  337:1378-1379. 1991
  • Lack of effect of pregnancy on outcome of melanoma.  337:653-655. 1991
  • Detection of Pneumocystis carinii with DNA amplification.  336:451-453. 1990
  • Ureaplasma and mycoplasma CNS infections in newborn babies.  335:658-659. 1990
  • Rapid detection of herpes-simplex-virus DNA in cerebrospinal fluid of patients with herpes simplex encephalitis.  335:440-441. 1990
  • Difficulties with sputum induction for diagnosis of Pneumocystis carinii pneumonia.  335:112. 1990
  • Ganciclovir for lumbosacral polyradiculopathy in AIDS.  335:48-49. 1990
  • Post-kala-azar dermal leishmaniasis in the absence of active visceral leishmaniasis.  336:750. 1990
  • ACUTE RENAL FAILURE AFTER NEBULISED PENTAMIDINE.  333:1271-1272. 1989
  • NON-SPECIFIC MESANGIAL STAINING WITH ANTIBODIES AGAINST CYTOMEGALOVIRUS IN IMMUNOGLOBULIN-A NEPHROPATHY.  333:129-131. 1989
  • Non-specific mesangial staining with antibodies against cytomegalovirus in immunoglobulin-A nephropathy.  1:129-131. 1989
  • BRONCHIAL BLEEDING WITH NEBULISED PENTAMIDINE.  332:1488. 1988
  • ASSOCIATION OF UREAPLASMA UREALYTICUM INFECTION OF THE LOWER RESPIRATORY TRACT WITH CHRONIC LUNG DISEASE AND DEATH IN VERY-LOW-BIRTH-WEIGHT INFANTS.  332:240-245. 1988
  • NEBULISED PENTAMIDINE.  331:645-646. 1988
  • CHRONIC UREAPLASMA UREALYTICUM AND MYCOPLASMA HOMINIS INFECTIONS OF CENTRAL NERVOUS SYSTEM IN PRETERM INFANTS.  331:17-21. 1988
  • DIFFERENCE BETWEEN HERPES SIMPLEX VIRUS TYPE I AND TYPE 2 NEONATAL ENCEPHALITIS IN NEUROLOGICAL OUTCOME.  331:1-4. 1988
  • TOXIC EFFECTS AFTER LASER DECOMPOSITION OF INTRAOCULAR GASES.  330:1517. 1987
  • AUTONOMIC NEUROPATHY IN AIDS.  330:343-344. 1987
  • GRISEOFULVIN TERATOLOGY, INCLUDING TWO THORACOPAGUS CONJOINED TWINS.  329:171. 1987
  • TREATMENT OF ACUTE RENAL FAILURE, SYMMETRICAL PERIPHERAL GANGRENE, AND SEPTICAEMIA WITH PLASMA EXCHANGE AND EPOPROSTENOL.  329:156. 1987
  • CYCLOSPORIN IN THERAPEUTIC DOSES INCREASES RENAL ALLOGRAFT VASCULAR RESISTANCE.  328:477-479. 1986
  • DESIGN OF THERAPEUTIC STUDIES IN HERPES SIMPLEX ENCEPHALITIS.  325:284-285. 1985
  • Design of therapeutic studies in herpes simplex encephalitis.  325:284-285. 1985
  • RACIAL DIFFERENCE IN THE PREVALENCE OF IgA-ASSOCIATED NEPHROPATHIES.  324:522. 1984
  • Racial difference in the prevalence of IgA-associated nephropathies..  2:522. 1984
  • MATERNAL TRANSMISSION IN HUNTINGTON'S DISEASE.  321:208-210. 1983
  • CANNABIS-ASSOCIATED PSYCHOSIS WITH HYPOMANIC FEATURES.  320:1364-1366. 1982
  • CYTOGENETICS OF B-CELL LINEAGE ACUTE LYMPHOCYTIC LEUKAEMIAS OF CHILDHOOD.  320:1334-1335. 1982
  • REPEATED SUPPRESSION OF CREUTZFELDT-JAKOB DISEASE WITH VIDARABINE.  320:564-565. 1982
  • HERPES SIMPLEX ENCEPHALITIS AND CLINICAL TRIAL DESIGN.  319:1013. 1982
  • CELLULAR EXPRESSION OF WISKOTT-ALDRICH ALLELE.  315:601-602. 1980
  • USE OF PROSTACYCLIN IN PERSISTENT FETAL CIRCULATION.  314:638. 1979
  • HYPOXÆMIA IN VENTILATED NEONATES AFTER PANCURONIUM PARALYSIS.  313:877. 1979
  • Hypoxaemia in ventilated neonates after pancuronium paralysis.  1:1095. 1979
  • RENAL PROSTAGLANDINS IN SYSTEMIC LUPUS ERYTHEMATOSUS.  312:553-555. 1978
  • HUMORAL IMMUNITY IN MYASTHENIA GRAVIS: RELATIONSHIP TO DISEASE SEVERITY AND STEROID TREATMENT.  312:96. 1978
  • VIABILITY OF THE PREMATURE FETUS IN DISTRESS.  311:764-765. 1978
  • SODIUM EXCRETION AND SYMPATHETIC ACTIVITY IN RELATION TO SEVERITY OF HYPERTENSIVE DISEASE.  308:471. 1976
  • SEX-CHROMOSOME ABNORMALITIES IN HUSBANDS AND WIVES.  305:333-334. 1975
  • PROTEIN REQUIREMENT.  304:712-714. 1974
  • EVOLUTION OF KWASHIORKOR AND MARASMUS.  304:458. 1974
  • TREATMENT OF CHRONIC MONILIASIS WITH LYMPHOCYTE TRANSFUSIONS.  296:569. 1970
  • Adaptation to low-protein intakes..  1:105. 1969
  • Jejunal absorption of aminoacids in nutritional rickets..  2:1428. 1969
  • Serum-lipids in bushmen..  2:684. 1968
  • Recovery from massive amitriptyline overdosage..  1:1256. 1968
  • International Standard Serial Number (issn)

  • 0140-6736
  • Electronic International Standard Serial Number (eissn)

  • 1474-547X